Back to top

Analyst Blog

Isis Pharmaceuticals, Inc. (ISIS - Analyst Report) earned another milestone payment with partner GlaxoSmithKline (GSK - Analyst Report) adding a development candidate, ISIS-GSK3Rx, under its collaboration with Isis Pharma.

Isis Pharma earned a milestone payment of $7 million related to the advancement of ISIS-GSK3Rx, which is being developed using antisense technology to inhibit the production of an undisclosed target to treat a common viral infection.  While Isis Pharma is responsible for the development of ISIS-GSK3Rx to the phase II proof-of-concept stage, Glaxo has an exclusive option to in-license the program thereafter and develop and commercialize the candidate.

We are positive on Isis Pharma’s agreement with Glaxo and other companies including Biogen (BIIB - Analyst Report), which not only validate the company’s antisense technology but also provide Isis Pharma with funds in the form of upfront, milestone and other payments.

Under the Glaxo deal, which is focused on the discovery and development of new therapeutics against targets for rare and/or serious diseases, Isis Pharma stands to receive additional pre-licensing milestone payments with the advancement of ISIS-GSK3Rx. Moreover, Isis Pharma may receive double-digit royalties on sales of ISIS-GSK3Rx.

Isis Pharma currently carries a Zacks Rank #3 (Hold). We view Kynamro’s Jan 2013 approval in the U.S. as a major milestone for the company. We are also pleased with Isis Pharma’s progress with its pipeline. However, we remain concerned about Kynamro’s sales ramp up which could be slow due to the reimbursement process and the process of finding eligible patients.

At present, Actelion (ALIOF) looks well-positioned with a Zacks Rank #1 (Strong Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
UTD THERAPE… UTHR 117.83 +28.51%
TRIQUINT SE… TQNT 20.67 +6.52%
RF MICRO DE… RFMD 12.47 +6.04%
VASCO DATA… VDSI 14.77 +4.68%
BANCO DO BR… BDORY 15.53 +3.95%